World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
88
Citations
47961
World Ranking
12906
National Ranking
1211

Kei Muro publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Kei Muro sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 817 publications — 88th percentile

88% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Kei Muro D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Kei Muro sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 88 D-Index — 36th percentile

36% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Kei Muro is affiliated with the National Cancer Research Institute, UK in the United Kingdom. Their research primarily spans the field of Medicine with a strong focus on Oncology and related subfields.

Muro's main areas of research include Oncology, Pulmonary and Respiratory Medicine, Surgery, Gastroenterology, and Cancer Research. Within these, key topics addressed are Gastric Cancer Management and Outcomes, Colorectal Cancer Treatments and Studies, Cancer Immunotherapy and Biomarkers, Esophageal Cancer Research and Treatment, Gastrointestinal Tumor Research and Treatment, Lung Cancer Treatments and Mutations, and Cancer Treatment and Pharmacology.

Their frequent co-authors include Shigenori Kadowaki, Toshiki Masuishi, Yukiya Narita, Kentaro Yamazaki, and Takatsugu Ogata, indicating ongoing collaborative research efforts in their field.

Kei Muro has contributed to several recent papers demonstrating a focus on immunotherapy and clinical trials in gastrointestinal and colorectal cancers:

  • Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer, 2020, Journal of Clinical Oncology
  • Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials, 2021, JAMA Oncology
  • Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer, 2023, JAMA
  • Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study), 2020, Journal of Clinical Oncology
  • Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial, 2021, Gastric Cancer

Their publication record includes frequent contributions to the following journals:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Gastric Cancer
  • Esophagus
  • International Journal of Clinical Oncology

Best Publications

  • ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

    E. Van Cutsem;A. Cervantes;R. Adam;A. Sobrero

  • Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer

    Toshiaki Watanabe;Michio Itabashi;Yasuhiro Shimada;Shinji Tanaka

  • Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

    Hansjochen Wilke;Kei Muro;Eric Van Cutsem;Sang Cheul Oh

  • Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

    Yoon Koo Kang;Narikazu Boku;Taroh Satoh;Min Hee Ryu

  • Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial

    Charles S. Fuchs;Toshihiko Doi;Raymond W. Jang;Raymond W. Jang;Kei Muro

  • Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

    Kohei Shitara;Mustafa Özgüroğlu;Yung-Jue Bang;Maria Di Bartolomeo

  • Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

    Kei Muro;Hyun Cheol Chung;Veena Shankaran;Ravit Geva

  • Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort

    Laura Q.M. Chow;Robert Haddad;Shilpa Gupta;Amit Mahipal

  • Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin.

    Y Matsumura;T Hamaguchi;T Ura;K Muro

  • Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer

    Takashi Kojima;Manish A Shah;Kei Muro;Eric Francois

  • Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer

    Toshiaki Watanabe;Michio Itabashi;Yasuhiro Shimada;Shinji Tanaka

  • EJ-3Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer

    Kei Muro

  • Everolimus for previously treated advanced gastric cancer: Results of the randomized, double-blind, phase III GRANITE-1 study

    Atsushi Ohtsu;Jaffer A. Ajani;Yu Xian Bai;Yung Jue Bang

  • Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS.

    T. Yoshino;D. Arnold;H. Taniguchi;G. Pentheroudakis

  • Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer

    Ryan B. Corcoran;Thierry Andre;Chloe E. Atreya;Jan H.M. Schellens

  • Definitive Chemoradiotherapy for T4 and/or M1 Lymph Node Squamous Cell Carcinoma of the Esophagus

    Atsushi Ohtsu;Narikazu Boku;Kei Muro;Keisho Chin

  • BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer

    T Yokota;T Ura;N Shibata;D Takahari

  • Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial

    Toshihiro Kudo;Yasuo Hamamoto;Ken Kato;Takashi Ura

  • TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial

    Takayuki Yoshino;Nobuyuki Mizunuma;Kentaro Yamazaki;Tomohiro Nishina

  • Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012.

    Ranee Mehra;Ranee Mehra;Tanguy Y. Seiwert;Shilpa Gupta;Shilpa Gupta;Jared Weiss

Frequent Co-Authors

Kohei Shitara
Kohei Shitara Yahoo (United Kingdom)
Narikazu Boku
Narikazu Boku St. Marianna University School of Medicine
Atsushi Ohtsu
Atsushi Ohtsu Juntendo University
Takayuki Yoshino
Takayuki Yoshino University of Tsukuba
Toshihiko Doi
Toshihiko Doi Okayama University
Hyun Cheol Chung
Hyun Cheol Chung Yonsei University
Yasushi Yatabe
Yasushi Yatabe Nagoya University
Hideo Baba
Hideo Baba Kumamoto University
Keitaro Matsuo
Keitaro Matsuo Nagoya University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn't always mean becoming a physician. There are many alternative online pathways that offer flexible entry points into the healthcare field. For example, online bsn programs for non nurses are designed for students from non-nursing backgrounds, making it easier to transition into nursing with an undergraduate degree in another field.

If you're interested in the administrative side of healthcare, you can consider enrolling in a health administration degree program online. These accelerated degrees can prepare you for management roles in hospitals, clinics, and other health organizations.

For those looking for a career that requires less clinical interaction, many choose to pursue roles through medical billing and coding schools online. These programs often have flexible schedules and can qualify you for in-demand positions in medical offices or insurance companies.

Additionally, if standardized admissions tests are a barrier, look for nursing schools that don't require teas test. This can make the application process quicker and more accessible for many aspiring nurses.

Best Scientists Citing Kei Muro

Trending Scientists

Recently Published Articles